Standard BioTools
LAB
109 hedge funds and large institutions have $179M invested in Standard BioTools in 2022 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 26 increasing their positions, 43 reducing their positions, and 24 closing their positions.
8.87% less ownership
Funds ownership: 73.59% → 64.72% (-8.9%)
10% less funds holding
Funds holding: 121 → 109 (-12)
19% less capital invested
Capital invested by funds: $220M → $179M (-$40.8M)
40% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 43
50% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 24
76% less call options, than puts
Call options by funds: $214K | Put options by funds: $877K
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$9.23M |
| 2 |
PVI
Pura Vida Investments
New York
|
+$2.94M |
| 3 |
FAM
Fred Alger Management
New York
|
+$1.38M |
| 4 |
NIM
Needham Investment Management
New York
|
+$910K |
| 5 |
Rockefeller Capital Management
New York
|
+$390K |
Top Sellers
| 1 |
O
OrbiMed
New York
|
-$15M |
| 2 |
TM
Tikvah Management
Charlotte,
North Carolina
|
-$4.9M |
| 3 |
RP
Repertoire Partners
New York
|
-$3.45M |
| 4 |
PCMI
Paradigm Capital Management Inc
Albany,
New York
|
-$3.02M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$2.74M |
LAB Hedge Fund Activity: Q1 2022 in Review
109 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q1 2022, worth a combined $179M — down 19% from $220M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of LAB and 12 opened new positions — a net loss of 12 holders — while 43 trimmed existing stakes and 26 added.
The largest buyer was Morgan Stanley, adding an estimated $9.23M. The largest seller was OrbiMed, exiting entirely with an estimated $15M sold.
- 109 institutional investors held Standard BioTools (LAB) as of Q1 2022, down from 121 in Q4 2021.
- Funds reported $179M of Standard BioTools stock for Q1 2022, down 19% quarter-over-quarter.
- 12 funds opened new Standard BioTools positions in Q1 2022 and 24 closed out, a net change of -12 holders.
- The largest Standard BioTools buyer in Q1 2022 was Morgan Stanley, an estimated $9.23M added.
- The largest Standard BioTools seller in Q1 2022 was OrbiMed, an estimated $15M sold.
Based on aggregated 13F filings for Q1 2022.